Background {#s1}
==========

Warfarin is the most commonly prescribed oral anticoagulant worldwide. It has a narrow therapeutic range with a large inter-individual variability of dose requirements and needs cumbersome monitoring of the international normalized ratio (INR) to avoid over-anticoagulation (INR\>3). Over-anticoagulation is associated with higher haemorrhagic risk, and bleeding represents the major complication of warfarin therapy \[[@SFU112C1]\]. Recently, the association between over-anticoagulation and acute kidney injury (AKI) has been described and named warfarin-related nephropathy (WRN) \[[@SFU112C2]\]. WRN is associated with glomerular haemorrhage with tubular obstruction by red blood cell (RBC) casts and affects more frequently patients with known chronic kidney disease (CKD) \[[@SFU112C3]\]. Since WRN represents a severe complication with a poor renal prognosis \[[@SFU112C4]\], the identification of patients at risk is important. In 2007 the Food and Drug Administration added pharmacogenetic information to the warfarin product label suggesting the evaluation of *CYP2C9* and *VKORC1* polymorphisms to establish the initial dose and reduce the risk of over-anticoagulation in warfarin-sensitive patients, although the test is costly and its applicability is still under evaluation \[[@SFU112C5]--[@SFU112C7]\]. So far no data are available regarding the warfarin pharmacogenetic profile in WRN affected patients. We report the case of a CKD patient with biopsy proven WRN that was a carrier of *CYP2C9P\*3* variant, a cytochrome polymorphism associated with higher risk of over-anticoagulation and bleeding. This is the first report suggesting an association with this genetic variant and WRN. Finally, we illustrate the clinical response of WRN to steroid treatment.

Case report {#s2}
===========

A 73-year-old Caucasian man with stage 3 CKD was admitted for worsening of renal function. Some weeks before he developed dyspepsia, anorexia, weight loss, asthenia and nocturia. He was initially accepted to another hospital and discharged with the diagnosis of stage 5 CKD. During this first hospitalization he declined the surgery to create an arteriovenous fistula (AVF) for haemodialysis and refused renal replacement therapy. The medical history revealed that he had hypertension and atrial fibrillation. Medications included pantoprazole, darbepoetin, bisoprolol and warfarin. Physical examination was substantially normal, BMI was 28 kg/m^2^ and blood pressure was 140/75 mmHg. Renal ultrasound demonstrated normal dimensions with preserved cortical thickness and no obstruction. Chest X-ray and abdominal CT scan were normal. The admission serum creatinine (sCr) was 6.96 mg/dL (eGFR 8 mL/min/1.73 m^2^), while 1 year before sCr was 1.3 mg/dL (eGFR 58 mL/min/1.73 m^2^). Urinalysis demonstrated significant proteinuria (2.46 g/24 h) and erythrocyturia (1739 RBC/µL). Serum albumin concentration was normal (4.1 g/dL) and a small monoclonal component (IgG k \< 0.1 g/dL) was found without Bence-Jones protein at urinalysis. LDL cholesterol was 210 mg/dL. A serological workup, including C3/C4, ANCA, ANA, anti-DNA, anti-GBM, viral serology and tumour markers, was negative. INR at admission was 1.52, but the patient referred many recent episodes of over-anticoagulation, and he had discontinued the oral anticoagulant. In the next days sCr progressively increased to 8.20 mg/dL, and we performed a kidney biopsy.

Kidney histology demonstrated modest matrix expansion with focal segmental sclerosis associated with vascular hyalinosis and extensive and diffuse tubular damage; in the tubular lumina large and occlusive RBC casts were evident (Figure [1](#SFU112F1){ref-type="fig"}). Immunofluorescence studies were negative, and ultrastructural evaluation was compatible with nephroangiosclerosis with secondary segmental/global glomerular sclerosis and confirmed the tubular damage. Fig. 1.Kidney biopsy findings. (**A**) Occlusive RBC casts in tubules (PAS stain; original magnification ×40). (**B**) Tubular obstruction by RBC casts and tubular damage also involving tubules without RBC cast obstruction (PAS stain; original magnification ×60).

The *CYP2C9\*2, CYP2C9\*3, VKORC1--1639G\>A* and *VKORC11173C\>T* polymorphisms were determined by real-time PCR (Lightcycler^®^, Roche). Genetic analysis was consistent with warfarin sensitivity and increased haemorrhagic risk since the patient was wild-type for *VKORC1* and homozygous for *CYP2C9\*3* allele.

The patient was treated by sodium bicarbonate for 2 weeks in the hope of obtaining cast washout, but renal function did not improve. We then started corticosteroid therapy with prednisone 1 mg/kg/die and immediately sCr began to decrease to a value of 4.44 mg/dL (eGFR = 14 mL/min/1.73 m^2^) after 3 months (Table [1](#SFU112TB1){ref-type="table"}). Thus, the need for immediate dialysis was avoided. Table 1.Laboratory findings according to clinical phase and therapyData at baseline (1 year before)Data at first hospitalizationData at admission to our divisionData after warfarin withdrawal and hydrationData at start of prednisone 1 mg/kg/dayData 3 months after starting prednisoneKidney functionAzotemia (mg/dL)ND167148135133150Creatinine (mg/dL)1.35.706.967.478.24.44eGFR MDRD (mL/min/1.73 m^2^)831088714UrinalysisErythrocyturia (RBC/µL)ND17305001546470Proteinuria (g/24 h)0.522.46ND0.620.51Other findingsINRNA1.451.601.051.021.05Albumin (g/dL)ND3.74.1ND3.43.30Leucocytes (cell/µL)617039204530498057009610Red blood cells (cell/µL)459026903170340037402930Haemoglobin (g/dL)13.88.79.910.611.89.40PCR (mg/L)409.67.3ND1.4\<1ANA/ENA/Anti-DNA/Anti-GBMNDNegNegNegNegNegC3/C4 (mg/dL)ND85/2681/25NDNDNDWarfarin pharmacogenetic profileCYP2C9NDNDCYP2C9/\*1\*3VKORC1NDNDWT[^1][^2]

Discussion {#s3}
==========

Causes of warfarin-dependent AKI include acute interstitial nephritis, atheroembolism, direct mesangial damage and WRN, a newly recognized syndrome characterized by glomerular haemorrhage with tubular obstruction by RBC casts. Although the first description dates back only to 2000 \[[@SFU112C8]\], WRN has been reported as a frequent complication of warfarin treatment affecting up to 30% of CKD patients \[[@SFU112C3], [@SFU112C9], [@SFU112C10]\]. The present report describes the case of a CKD patient who experienced many episodes of over-anticoagulation before developing severe kidney failure, but WRN was not suspected during the first hospitalization. When he was admitted to our division pre-renal and post-renal AKI were excluded as well as atheroembolism; rapidly progressive glomerulonephritis appeared unlikely. The clinical history did not mention drugs commonly associated with interstitial nephritis and was dominated by previous over-anticoagulation episodes and hypertension. Kidney biopsy definitively excluded these forms demonstrating a WRN since histological findings met the criteria previously described by Brodsky *et al.* \[[@SFU112C2]\]. We suggest that WRN should always be considered as a possible cause of AKI when episodes of over-anticoagulation are described, and kidney biopsy should be performed to confirm the diagnosis of this serious warfarin complication. Patients with CKD, hypertension, diabetes and cardiovascular disease should be considered at risk since these conditions are associated with WRN development \[[@SFU112C2], [@SFU112C9], [@SFU112C10]\].

The patient had significant proteinuria that is not part of WRN clinical expression. Kidney histology demonstrated a secondary focal glomerulosclerosis in a context of nephroangiosclerosis that explained this finding. This observation highlights the central role of renal biopsy which identified the cause of kidney failure and described the underlying coexisting nephropathy. Furthermore, renal biopsy could contribute to a better understanding of WRN pathogenesis. Ozcan and collegues reproduced WRN in a 5/6 nephrectomy rat model confirming the pathogenetic role of glomerular haemorrhage and tubular obstruction. The rats developed secondary focal segmental glomerulosclerosis after nephrectomy, and CKD progression exposed them to higher risk of WRN when over-anticoagulation occurred, resembling the case we reported \[[@SFU112C11], [@SFU112C12]\]. Considering these features, the patient was treated by warfarin discontinuation, hydration and sodium bicarbonate but no clinical response was obtained.

Interestingly, haematuria and haemoglobinuria may directly induce kidney damage even without tubular obstruction. Some observational reports indicate that early steroid administration could accelerate recovery of renal function after gross haematuria \[[@SFU112C13]\]. Although no data are available about steroid use in WRN with microscopic haematuria, we started this therapy obtaining a good response with partial recovery of renal function. The patient remained at CKD stage 5 but avoided dialysis. To the best of our knowledge, this is the first report describing WRN clinical response to steroid treatment. Though it needs to be confirmed, we consider this a fascinating finding since it suggests a possible therapeutic strategy for this nephropathy and a less mechanical pathogenesis of the renal damage. Notably, in this case kidney function did not completely recover confirming that WRN represents a severe warfarin complication with a poor renal prognosis \[[@SFU112C4], [@SFU112C9]\].

To prevent this complication it is necessary to identify patients at risk and to individualize the correct warfarin dose. Warfarin-related haemorrhage is 2-fold more common in CKD patients with respect to the general population \[[@SFU112C14]\], and WRN is more frequent in patients with a pre-existing nephropathy. The study of warfarin pharmacogenetics could be useful to identify patients who require lower doses. Warfarin is metabolized by liver cytochrome P450-CYP2C9 and acts as a vitamin K antagonist (VKAs) inhibiting the vitamin K epoxide reductase enzyme complex (VKORC1). CYP2C9 and VKORC1 are, respectively, encoded by *CYP2C9* and *VKORC1* genes. Some polymorphisms of these genes are associated with both warfarin metabolism impairment and higher haemorrhagic risk \[[@SFU112C5]\]. Recently, Limdi *et al.* \[[@SFU112C14]\] demonstrated that CKD patients require lower warfarin doses, and the dose adjustments should take into account both kidney function and *CYP2C9* and *VKORC1* genotypes. In the case of our patient, warfarin dose had not been titrated according to the pharmacogenetic profile, and the patient experienced many episodes of over-anticoagulation. The genetic study demonstrated that he was homozygous for *CYP2C9\*3* variant, which is a common European ancestry allele that reduces warfarin metabolism by 80--90% exposing the carriers to the greatest risk of bleeding \[[@SFU112C15]\]. In contrast, *−1639G\>A* and *1173C\>T* non-coding variants are associated with warfarin sensitivity and reduced dose requirements, but they are not associated with haemorrhagic events. On the basis of our observations, the *CYP2C9\*3* genetic variant might be associated with WRN development, suggesting for the first time a link between WRN and this polymorphism. Although it needs to be confirmed, this observation is particularly interesting given that WRN has an unfavorable prognosis and warfarin pharmacogenetics might be useful to identify patients at risk of complications. Warfarin pharmacogenetic-based algorithms could be used to establish both the initiation and maintenance dose minimizing the risk of over-anticoagulation and WRN development.

In conclusion renal biopsy should always be considered to identify WRN in patients developing AKI when over-anticoagulation is described. WRN is a serious complication with a poor renal prognosis and requires the development of successful therapeutic strategies. In our experience corticosteroids might play a role in WRN treatment. Finally, the *CYP2C9\*3* polymorphism could represent a genetic variant which identifies patients at risk for WRN. In general warfarin pharmacogenetics may indicate a genetic predisposition to WRN and act as a guide for dose requirements in CKD patients.
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[^1]: Corticosteroids allowed a partial recovery of kidney function as demonstrated by data obtained after 3 months of treatment.

[^2]: ND, not determined; NA, not available; Neg, negative; RBC, red blood cell; WT, wild-type gene.
